
Opinion|Videos|December 18, 2024
Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
Key Takeaways
Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
TULSA preserves penile length vs robotic prostatectomy in CAPTAIN trial
2
The UroOnc Minute: Optimizing Patient Follow-Up in Urologic Oncology, With Jason Hafron, MD
3
Can Aydogdu, MD on using ctDNA to predict nodal metastases at cystectomy
4
KEYNOTE-B15 data on enfortumab vedotin plus pembrolizumab in MIBC published in NEJM
5








